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Abstract
Background:  The recently discovered adult neural stem cells, which maintain continuous
generation of new neuronal and glial cells throughout adulthood, are a promising and expandable
source of cells for use in cell replacement therapies within the central nervous system. These cells
could either be induced to proliferate and differentiate endogenously, or expanded and
differentiated in culture before being transplanted into the damaged site of the brain. In order to
achieve these goals effective strategies to isolate, expand and differentiate neural stem cells into the
desired specific phenotypes must be developed. However, little is known as yet about the factors
and mechanisms influencing these processes. It has recently been reported that pituitary adenylate
cyclase-activating polypeptide (PACAP) promotes neural stem cell proliferation both in vivo and in
vitro.
Results:  We used cDNA microarrays with the aim of analysing the transcriptional changes
underlying PACAP induced proliferation of neural stem cells. The primary neural stem/progenitor
cells used were neurospheres, generated from the lateral ventricle wall of the adult mouse brain.
The results were compared to both differentiation and proliferation controls, which revealed an
unexpected and significant differential expression relating to withdrawal of epidermal growth factor
(EGF) from the neurosphere growth medium. The effect of EGF removal was so pronounced that
it masked the changes in gene expression patterns produced by the addition of PACAP.
Conclusion: Experimental models aiming at transcriptional analysis of induced proliferation in
primary neural stem cells need to take into consideration the significant effect on transcription
caused by removal of EGF. Alternatively, EGF-free culture conditions need to be developed.
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Background
During the last decade it has become evident that neuro-
genesis occurs in certain restricted regions of the adult
mammalian brain, particularly in the dentate gyrus of the
hippocampus and the subventricular zone (SVZ) of the
lateral ventricle [1-3]. The neurogenic cells in these areas
have been isolated and can be propagated in vitro where
they form clonal aggregates of cells denoted neurospheres
[4,5]. However, there seems to be some differences
between the populations of neurospheres obtained from
the different regions. SVZ neurospheres possess the two
cardinal properties of stem cells, i.e. they are self-renewa-
ble and multipotent [5], whereas hippocampal neuro-
spheres appear to be more precursor cell-like, in that they
are more limited in their self-renewal and individual
spheres exclusively give rise to neurons or glia [6].
The rather recently discovered neural stem cell (NSC)
population, sustaining continuous neurogenesis in the
adult brain, has become a promising source of cells for
cell-replacement therapies for various neurological dis-
eases [7-9]. Cell replacement with fetal mesencephalic or
striatal tissue has previously been shown to lead to func-
tional improvement in patients with Parkinson's disease
and Huntington's disease [10-12]. However, the use of
fetal cells is hampered by a number of hurdles, in addition
to ethical concerns. Fetal tissue is only available in limited
quantities and the fetal cells are mostly postmitotic and
cannot be expanded, nor stored for long periods of time.
Furthermore these cell populations are heterogeneous,
and their purity and viability cannot be reliably control-
led, perhaps explaining the variation in functional out-
come between different transplantation studies. In
contrast, stem cells represent a source of cells that is more
readily obtainable, expandable and could potentially be
maintained as a more homogeneous, pure cell popula-
tion. By supplying the appropriate factors endogenous
stem/progenitor cells could be recruited to generate new
neural or glial cells of specific phenotypes (e.g. dopamin-
ergic neurons in Parkinson's disease or oligodendrocytes
in multiple sclerosis). Alternatively the NSCs could be
expanded and properly manipulated in vitro, before trans-
planting them into the appropriate area of the brain. Both
strategies have been evaluated with limited but promising
success [13-16]. However, more knowledge on the control
of NSC proliferation and differentiation into specific phe-
notypes, both in vivo and in vitro, is needed before any
clinical trails can be made.
Some factors stimulating neurogenesis are already known
(for reviews see [7,8,17]). These include epidermal growth
factor (Egf), basic fibroblast growth factor (Fgf2), brain-
derived neurotrophic factor (Bdnf) and transforming
growth factor-α (Tgfa). Recently there was a report that
neurogenesis can also be stimulated through a G-protein
coupled receptor [18]. The pleiotropic neuropeptide pitu-
itary adenylate cyclase-activating polypeptide (PACAP)
promotes NSC proliferation both in vivo and in vitro, via
the PACAP receptor 1 (PAC1). PACAP belongs to the
vasoactive intestinal peptide (VIP)/secretin/glucagon fam-
ily of peptides and exerts a number of biological effects in
addition to neurogenesis (for reviews see [19,20]).
We have recently performed a gene expression analysis of
primary neural stem cells (neurospheres), demonstrating
the need to consider biological fluctuations of these cells
when performing comparative transcriptome analysis
[21]. Here we continue the work to investigate the tran-
scriptional changes underlying the proliferative effect of
PACAP on SVZ neurospheres by using microarrays,
including controls for differentiation and proliferation.
Results
To investigate the molecular changes underlying the pro-
liferative effects of PACAP we performed a gene expres-
sion analysis using a 16 k cDNA microarray. The
experimental design depicted in Figure 1 was utilised.
NSCs were isolated from a pool of lateral ventricular wall
tissue from 15 mice and grown in culture as neurospheres,
after which they were dissociated and cultured to form
secondary neurospheres. Secondary neurospheres were
dissociated and split into eight parallel cultures. The cells
were used to study the culture variance and three different
treatments, each replicated in two individual cultures
(indicated by letters a and b in Figure 1.) We used ampli-
fication and culture replicates to control for technical and
biological variation respectively, and controls for differen-
tiation and proliferation activation to verify our results.
In all comparisons undifferentiated neurospheres (NS),
maintained in culture medium supplemented with epi-
dermal growth factor (EGF), was used as a reference con-
trol sample. In the first of three treatment regimes
neurospheres were induced to proliferate in response to
PACAP by replacing the EGF supplemented culture
medium with medium supplemented with PACAP. In the
proliferation control, the cells were induced to proliferate
in response to a transmembrane receptor agonist (TMR
agonist) by replacing EGF with the agonist in the neuro-
sphere culture medium. In the third treatment, the differ-
entiation control, neurospheres were induced to
differentiate into neurons, astrocytes and oligodendro-
cytes by replacing the EGF supplemented culture medium
with medium supplemented with fetal calf serum, and
plating the cells onto poly-D-lysine plates.
mRNA was isolated from all cell cultures and used in a
series of cDNA microarray hybridisations. To avoid exten-
sive passaging of the neurospheres, a limited amount of
cells were obtained, and the generated RNA was notBMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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Neurosphere culturing and experimental design Figure 1
Neurosphere culturing and experimental design. Neural stem/progenitor cells were isolated from the lateral ventricle 
wall region of brains from a pool of mice and grown as neurospheres. RNA was isolated from different treatments as indicated 
and used for subsequent microarray hybridisations. a and b indicate biological replicates. Each arrow represents the number of 
hybridisations, arrowhead represents labelling with Cy5 and arrow tail represents labelling with Cy3. Groups 1, 2 and 3 indi-
cate hybridisations grouped in the data analysis, to optimise the variance estimates for each gene. NS = neurosphere control, 
PACAP = pituitary adenylate cyclase-activating polypeptide treated samples, Prol Cont = proliferation control (transmembrane 
receptor agonist treated samples), Diff Cont = differentiation control (fetal calf serum treated, and solid support plated 
samples).
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sufficient for labelling and subsequent microarray analy-
sis. The RNA was therefore amplified using a previously
described protocol [22,23], that has recently also been
evaluated for neurosphere analysis [21]. The principle
relies on incorporating a biotin moiety into the cDNA
during the first-strand cDNA synthesis, by using a bioti-
nylated oligo(dT) primer. The population of cDNAs is
fragmented and the biotinylated 3'ends captured onto a
streptavidin-coated solid support. The isolated cDNA tags
are released from the support, amplified by PCR and
labelled for subsequent microarray hybridisation.
Amplified and labelled cDNA from each treated sample
was hybridised against the neurosphere control sample
(NS). In order to measure the technical variation self-to-
self hybridisations were made with material from NS sam-
ple a. In addition, to measure the variation between two
identical cultures, the two NS replicates (a and b) were
hybridised against each other. For each comparison two
replicate and two dye-swap hybridisations were
performed.
We have previously shown that neurosphere culture pas-
saging or prolonged culturing per se, is sufficient to
induce differential expression and that this should be
taken into account in the design of the experiment [21].
To address these issues, i.e. to get a variance measure from
as many slides as possible, the results from all hybridisa-
tions were divided into three groups prior to data analysis,
as indicated in Figure 1. Group 1 contains eight hybridisa-
tions comparing the technical amplification replicates
(NS a-NS a) and the biological culturing replicates (NS a-
NS b). Groups 2 and 3 consist of sixteen hybridisations
each and include the NS a-NS b hybridisations as well as
one replicate of each treatment comparison (NS vs.
PACAP treated, NS vs. differentiation control and NS vs.
proliferation control). This scheme allows for estimation
of technical and biological noise (Group 1). Also, by
using the NS a and NS b samples as reference samples in
each group, the "contrasts" (i.e. the calculated differences
between two treatments) can be calculated and compared
between the groups (data not shown). The data in all
three groups was filtered (for details see Methods) and
print-tip lowess normalised using identical criteria. For
each group individual gene-wise variances were calcu-
lated, and taken into account in the identification of dif-
ferentially expressed genes using the empirical Bayes
moderated t-test [24-26]. For each comparison the log-
odds ratio (B-value) was used to rank the genes in order of
evidence for differential expression. Higher B-value indi-
cates higher probability of differential expression.
In order to investigate the magnitude of differential
expression in each comparison the M-value (log2(sample
X intensity/sample Y intensity)) for each gene was com-
pared to the corresponding B-value (Figure 2). Genes with
a high M-value usually receive a high B-value, which gives
the plots the characteristic volcano shape. Figure 2 shows
that the number of differentially expressed (DE) genes
and the magnitude of differential expression is much
lower for the technical and biological replicates than for
the treated samples. This indicates that the RNA amplifi-
cation and the biological fluctuations during culturing do
not contribute substantially to the observed differential
expression for PACAP and control treatments. Notewor-
thy, the distributions of B- and M-values are very similar
for all treated samples, implicating that the magnitude of
gene expression changes are similar for all treatments. The
correlation between the replicated comparisons in Groups
2 and 3 was investigated by visualising the M-values from
a comparison in Group 2 against the corresponding M-
values in Group 3 (Figure 3). This shows that there is a
high correlation between the replicates, with correlation
coefficients ranging from 0.85 to 0.88. For the A-values
(intensity values) the correlations are even higher ranging
from 0.996 to 0.997 (data not shown). The M-value cor-
relations between the contrasts were analysed in a similar
fashion, but yielded much lower correlation coefficients
(0.10 for PACAP treatment vs. proliferation control, 0.33
for differentiation control vs. proliferation control and
0.56 for differentiation control vs. PACAP treatment, data
not shown). These low correlations are a consequence of
the small differences between the contrasts as shown in
the M-value distributions for the different comparisons
(figure 4)
To further explore the overlap between DE genes in the
replicated treatments Venn diagrams shown in Figure 5
were created. The comparisons include genes with a Holm
adjusted p-value < 0.0001 and an M-value > +/- 0.6 (cor-
responding to a fold change > 1.5). Also included in the
comparison are 29 DE genes (corresponding to 40 redun-
dant probes on array) identified in the NS a-NS b compar-
ison that could be considered as technical noise. Figure 5
shows that the overlap between the biological replicates is
high. For all three treatments the majority of the genes
(60–70%) are differentially expressed in both replicates;
814 genes (1109 probes) for the NS vs. PACAP treatment,
741 genes (986 probes) for the NS vs. proliferation con-
trol and 604 genes (797 probes) for the NS vs. differenti-
ation control. Also, a large proportion of the non-
overlapping genes showed a similar M-value in the two
groups, indicating that the true overlap is even higher. The
genes shared by both replicates for a certain treatment
were further compared between the different treatments
to visualise the effects of the different treatments on gene
expression levels. Surprisingly, the great majority of the
genes (435, 579 probes) fall within the overlap of all treat-
ments, further suggesting that the different stimuli results
in very similar effects on gene expression level.BMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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A likely explanation is that the removal of growth factor
(EGF) from the neurosphere culture medium, coinciding
with the treatment initiation, masks the effect on gene
expression changes caused by the different stimuli. To fur-
ther investigate whether the remaining unique DE genes
were true differences or related to the EGF effect we per-
formed additional analysis of the 213 (265 probes), 135
(168 probes) and 79 (92 probes), non-overlapping genes.
A comparison was made by taking the lists of the unique
genes for one treatment and visualising their correspond-
ing M-values in the other treatments (Figure 6). The
results depicted in Figure 6 demonstrate that the majority
of genes are clustered around the threshold values of the
criteria for differential expression, either with an M-value
just above or below 0.6 or with a p-value greater than
0.0001. Thus, the majority of unique (non-overlapping)
genes are borderline cases, nearly included in the category
of overlapping genes. Genes that would have been truly
unique to the treatment in question would have had M-
values in both replicates that were centred round zero. No
such genes can be found when comparing the results from
NS vs. PACAP treatment and NS vs. proliferation control.
A few genes can be found when comparing NS vs. differ-
entiation control to either one of the other two treat-
ments, indicating that the serum treatment gives a
somewhat more different gene expression profile, as
B-value distributions for each comparison Figure 2
B-value distributions for each comparison. The x-axis shows the M-value (log2(Cy5/Cy3)) for each gene and the y-axis 
the corresponding B-value (calculated by an empirical Bayes moderated t-test).The B-value scores the genes according to their 
probability of differential expression. Higher B-value means higher probability of differential expression. Dotted lines are drawn 
at M-values 0.6 and -0.6, i.e. at a 1.5-fold difference in signal intensity between the compared samples, and at B = 9.3, corre-
sponding to a Holm adjusted p-value of 0.0001. These values correspond to the thresholds set for differential expression in this 
study.BMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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expected. To facilitate further analysis of the results, anno-
tated gene lists corresponding to the genes that were con-
sidered differentially expressed only in the NS vs. Diff
Cont comparison, or shared between NS vs. PACAP and
NS vs. Prol Cont comparisons are provided [see addi-
tional file 1 and additional file 2, respectively]. The com-
plete results for all comparisons are available in
ArrayExpress using experiment accession number E-
MEXP-322.
These findings indicate that the differentially expressed
genes in the different treatments are due to the withdrawal
of EGF rather than to the treatment itself. A list of the 435
genes identified as the EGF treatment/withdrawal genes
(see Figure 5) is provided [see additional file 3]. A short
version of the list, with the top 40 genes, is shown in Table
1. The genes were further grouped and ranked according
to their Gene Ontology annotation. We focused on the
'Biological Processes' branch of the GO theme structure
and analysed the functional categories represented in the
data. In total, 241 genes received a functional annotation.
The results of the analysis, which was carried out at the
detail level 3 (intermediate level that gives a general over-
view of the data), are provided [see additional file 4]. The
themes with the highest representation were 'cell growth
and/or maintenance' (118 genes), 'nucleobase, nucleo-
side, nucleotide and nucleic acid metabolism' (65), 'pro-
tein metabolism' (46), 'signal transduction' (29),
'catabolism' (20) and 'organogenesis' (20). In general, the
list of expressed functional categories is enriched for vari-
ous metabolism-related themes, but further down also
contains themes such as 'cell adhesion', 'cell death',
'response to external stimulus' and 'cell-cell signalling'
Next we analysed the overrepresentation of functional cat-
egories by using the genes represented on the array as
background for the significance calculations. The top GO
terms of the biological process class overrepresented in
the data are shown in Table 2. A large proportion of these
GO themes are related to the cell cycle and/or DNA repli-
cation, as expected for EGF-related effects. Many of the
transcripts found and classified within "mitotic cell cycle"
and "DNA replication and chromosome cycle" are down-
regulated in the treated samples lacking EGF. In contrast
many genes within "neurogenesis", "organogenesis" and
"development" are up-regulated in these samples, proba-
bly reflecting the removal of inhibitory regulation on dif-
ferentiation as EGF is withdrawn from the culture
medium.
Discussion
We have recently performed a pilot study investigating
both the amplification technology and various neuro-
sphere isolation and culture conditions [21]. In that study
we could show a low technical variability in the microar-
ray analysis, large transcriptional differences between pas-
sages of neurospheres and a smaller differences between
parallel cultures. The variability is addressed in this study
by increasing the number of replicates, using parallel cul-
tures to improve the statistical power in identification of
differentially expressed genes. The observed differential
gene expression (Figure 2) is low for the culture and tech-
nical replicates, confirming previous findings, and has a
minor impact on the results obtained in the three treat-
ment comparisons.
The primary goal in this study was to identify the genes
activated by PACAP treatment. PACAP acts as a neuro-
transmitter or neuromodulator in the brain, and regulates
Graphs displaying the correlation between replicated samples Figure 3
Graphs displaying the correlation between replicated samples. The x-axis and y-axis display M-values (log2(Cy5/Cy3)) 
for replicated samples. The values of the Pearson correlation coefficient (r) and the coefficient of determination (R2) are also 
included.BMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
Page 7 of 15
(page number not for citation purposes)
the secretion of certain neurohormones. PACAP also acts
as a neurotrophic factor during brain development and as
a neuroprotective agent in the adult brain and acts via
three G-protein coupled receptors, PAC1 and the vasoac-
tive intestinal peptide receptors VIP1 and VIP2. In the
recent study [18] it was shown that PAC1 is expressed in
Box plots displaying the M-value (log2(Cy5/Cy3)) distribution for each comparison Figure 4
Box plots displaying the M-value (log2(Cy5/Cy3)) distribution for each comparison.
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the neurogenic regions of the adult mouse brain and in
neurospheres generated from the lateral ventricular wall
in the adult mouse. Importantly it was also shown that
PACAP stimulates proliferation of NSC in the brain and of
cultured neurospheres, and a number of new proliferation
targets were sought to be discovered by the array analysis
Correlation between biological replicates and between treatments Figure 5
Correlation between biological replicates and between treatments. The number of differentially expressed genes in 
each comparison are presented and compared. Genes with an M-value > | 0.6 | and a p-value < 0.0001, calculated by empirical 
Bayes moderated t-test and a Holm's adjustment for multiple testing are included. Figures without parentheses show the 
number of probes included. Figures within parentheses show the number of corresponding genes. NS = neurosphere control, 
PACAP = pituitary adenylate cyclase-activating polypeptide treated samples, Prol Cont = proliferation control (transmembrane 
receptor agonist treated samples), Diff Cont = differentiation control (fetal calf serum treated, and solid support plated 
samples).
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M-value analysis of non-overlaping genes from the treatment comparisons Figure 6
M-value analysis of non-overlaping genes from the treatment comparisons. M-values (log2(Cy5/Cy3)) for genes 
identified as DE in either only neurosphere vs. PACAP treatment (A), neurosphere vs. proliferation control (B) or neuro-
sphere vs. differentation control (C) are shown using data from the other two treatment comparisons. Colouring indicates if a 
gene reaches the statistical significance required for differential expression (black, both replicates have p-values < 0.0001; red, 
p-value in replicate a > 0.0001: green, p-value in replicate b > 0.0001). Dotted lines depict the cut-off values for scoring differ-
ential expression (M-value > | 0.6 |).
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of neurospheres. The previous study [18] also demon-
strated a synergistic proliferative effect of the combined
stimulation of EGF and PACAP. It has previously been
described that PAC1 signalling shows cross-talk to the sig-
nalling of receptor tyrosine kinase cascades, such as that
elicited by nerve growth factor (NGF), suggesting that
PACAP may act in concert with other molecules to maxi-
mize or regulate their effect [27]. In order to investigate
the PACAP effect without EGF interference, we chose to
culture the neurospheres for three days in the absence of
EGF, but presence of PACAP.
However, the obtained results could not demonstrate a
PACAP-specific transcriptional signature. Instead, by
comparing the differentially expressed genes from PACAP
treatment with control experiments representing
proliferation or differentiation activation we could con-
clude that the removal of EGF was the main contributor to
Table 1: Top differentially expressed genes in the overlap between all treatments.
Unigene ID Gene ID GeneName Avg M Stdev M Avg B Stdev B
Mm.305535 69719 Carbamoyl-phosphate synthetase 2 4.53 0.26 53.33 4.34
Mm.1239 14580 Glial fibrillary acidic protein 4.47 0.39 69.36 3.97
Mm.252063 17196 Myelin basic protein 3.84 0.57 47.80 7.00
Mm.200608 12759 Clusterin 3.72 0.54 60.76 7.92
Mm.240850 76960 Breast carcinoma amplified sequence 1 3.72 0.17 46.89 1.30
Mm.291129 70877 RIKEN cDNA 4921517J23 gene 3.68 0.44 49.64 6.06
Mm.1268 18823 Proteolipid protein (myelin) 1 3.64 0.49 51.72 4.02
Mm.305152 11816 Apolipoprotein E 3.62 0.46 45.79 11.39
Mm.334994 53867 Procollagen. type V. alpha 3 3.61 0.45 49.05 8.48
Mm.272443 64383 Sirtuin 2 3.33 0.34 72.98 3.98
Mm.7420 22153 Tubulin. beta 4 3.13 0.38 53.65 4.65
Mm.39053 71770 Adaptor-related protein complex 2. beta 1 subunit 2.92 0.61 32.53 10.40
Mm.228362 NA Transcribed locus 2.69 0.15 39.82 3.13
Mm.358573 11858 Ras homolog gene family. member N 2.68 0.39 52.12 7.88
Mm.276739 20665 SRY-box containing gene 10 2.65 0.34 33.25 1.34
Mm.241355 17136 Myelin-associated glycoprotein 2.57 0.59 32.28 6.80
Mm.278672 14810 Glutamate receptor. ionotropic. NMDA1 (zeta 1) 2.56 0.52 35.15 7.11
Mm.260601 242521 Kelch-like 9 (Drosophila) 2.54 0.41 44.19 9.26
Mm.192991 17748 Metallothionein 1 2.47 0.54 21.61 5.08
Mm.37199 14862 Glutathione S-transferase. mu 1 2.44 0.16 38.61 2.15
Mm.41580 69908 RAB3B. member RAS oncogene family -3.55 0.31 47.83 4.75
Mm.290563 12615 Centromere autoantigen A -3.14 0.16 49.02 3.58
NA NA GenBank ID: CX204578 -3.09 0.34 34.48 2.55
NA NA GenBank ID: CX207566 -2.99 0.27 51.46 6.04
Mm.273049 12443 Cyclin D1 -2.89 0.33 44.78 3.46
Mm.289747 107995 Cell division cycle 20 homolog (S. cerevisiae) -2.68 0.15 55.41 5.67
Mm.285723 14793 Cell division cycle associated 3 -2.65 0.08 42.97 0.95
Mm.24337 52033 PDZ binding kinase -2.58 0.12 40.31 2.70
Mm.29254 16009 Insulin-like growth factor binding protein 3 -2.49 0.29 41.37 3.97
Mm.233799 16010 Insulin-like growth factor binding protein 4 -2.46 0.31 23.86 5.98
Mm.16525 18817 Polo-like kinase 1 (Drosophila) -2.43 0.12 26.12 1.92
Mm.28038 52276 Cell division cycle associated 8 -2.39 0.12 30.79 5.44
Mm.4857 12323 Calcium/calmodulin-dependent protein kinase II. beta -2.38 0.49 42.14 5.06
Mm.335368 NA CDNA. clone:Y2G0133B03:ENSEMBL -2.35 0.25 50.92 4.35
NA NA GenBank ID: CX206925 -2.32 0.13 28.39 1.66
Mm.271711 21346 Transgelin 2 -2.25 0.12 38.33 1.70
Mm.4237 21973 Topoisomerase (DNA) II alpha -2.14 0.12 46.22 2.01
Mm.1408 11535 Adrenomedullin -2.07 0.17 26.68 5.70
Mm.37802 69544 WD repeat domain 5B -2.03 0.10 59.04 2.30
Mm.35389 13063 Cytochrome c. somatic -2.02 0.12 51.69 2.15
The top of the table shows genes that are up-regulated in the treated (EGF withdrawn) samples, compared to the undifferentiated neurospheres 
(NS) (positive M-values). The lower half of the table shows genes that are up-regulated in the NS sample (negative M-values). Average M- and B-
values for all comparisons (NS vs. PACAP, NS vs. Prol Cont and NS vs. Diff Cont) are shown, together with their standard deviations. All genes 
have a p-value < 0.0001, calculated by empirical Bayes moderated t-test and a Holm adjustment for multiple testing.BMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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the observed differential expression. We demonstrate this
by the large overlap in the Venn diagram of DE genes and
we could also conclude that the group of "unique" (non-
overlapping) genes were not truly unique by demonstrat-
ing that these would have been shared among the differ-
ent treatments if slightly less stringent criteria had been
used in the definition of differential expression. So why
does EGF removal have such a strong effect in comparison
to the addition of other factors, such as PACAP? EGF is an
extremely powerful mitogen for adult mouse neural stem
Table 2: Gene ontology analysis.
Biological process enriched in neurosphere 
(NS) control sample
No of DE genes in all 
treatments
No of genes on array Fisher Exact
mitotic cell cycle 35 136 3.840E-22
DNA replication and chromosome cycle 24 72 3.320E-18
cell cycle 43 307 2.360E-16
cell proliferation 46 362 7.620E-16
DNA replication 20 61 3.770E-15
S phase of mitotic cell cycle 20 62 5.400E-15
DNA-dependent DNA replication 11 24 1.160E-10
DNA metabolism 29 218 1.830E-10
DNA replication initiation 7 8 4.430E-10
mitosis 12 48 5.240E-08
M phase of mitotic cell cycle 12 48 5.240E-08
cell growth and/or maintenance 79 1411 2.740E-07
nuclear division 12 58 4.950E-07
M phase 12 61 8.830E-07
cellular physiological process 82 1564 2.770E-06
cytokinesis 11 63 8.760E-06
nucleosome assembly 6 21 5.920E-05
regulation of cell cycle 15 138 7.790E-05
physiological process 135 3454 6.310E-04
DNA packaging 9 80 1.750E-03
Biological process enriched in treated (PACAP. 
Prol Cont and Diff Cont) samples
No of DE genes in all 
treatments
No of genes on array Fisher Exact
microtubule-based process 7 64 1.340E-03
development 22 456 3.400E-03
neurogenesis 8 99 4.300E-03
organogenesis 14 243 4.390E-03
morphogenesis 15 282 6.730E-03
cytoskeleton organization and biogenesis 9 134 8.430E-03
organelle organization and biogenesis 10 175 1.650E-02
cellular process 65 2144 6.560E-02
cytoplasm organization and biogenesis 10 222 6.720E-02
lipid metabolism 8 173 8.570E-02
membrane lipid metabolism 3 42 9.840E-02
cell adhesion 7 162 1.360E-01
cell communication 27 835 1.440E-01
cell organization and biogenesis 12 331 1.620E-01
regulation of biological process 5 110 1.650E-01
ion transport 7 188 2.280E-01
cellular physiological process 45 1564 2.640E-01
cation transport 5 135 2.850E-01
cell death 5 144 3.330E-01
cell surface receptor linked signal transduction 9 286 3.440E-01
The most highly overrepresented gene ontology themes among the genes that were differentially expressed in all treatments. Analysis was 
restricted to themes of category biological process. Genes with M-value > | 0.6 | and p < 0.0001, calculated by empirical Bayes moderated t-test and 
a Holm adjustment for multiple testing, are included. Jacknife Fisher's exact probability test was used to identify over-represented themes in the 
data. Corresponding p-values are listed.BMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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cells, exhibiting a four-fold greater proliferative potency
than PACAP at 1 nM and 100 nM, respectively [18]. Such
a profound mitogenic effect as that elicited by EGF is
likely to require large alterations in levels of gene tran-
scription and consequently the removal of this agent
necessitates large reversals. PACAP, being a substantially
less powerful proliferative agent, may well trigger less dra-
matic transcriptional changes, be it on genes in common
(such as through the EGF pathway system) or not to those
utilized by EGF to promote mitogenesis. In essence, it
appears that transcriptional fluctuations induced by the
presence and absence of EGF dwarf that elicited by
PACAP, and indeed the TMR agonist and even differenti-
ating factors.
Consequently, the shared DE genes reflect the removal of
the mitogenic signal of EGF. Gene annotation analysis
also supports the conclusions by demonstrating a down-
regulation of proliferation signals and up-regulation of
differentiation signals in the treated neurosphere cultures.
Some of the genes observed in the differentiation control
are however unique, which probably reflects a broader
activation spectrum induced by fetal calf serum and solid
support plating, as compared to EGF withdrawal. Previous
studies of neurospheres using microarrays have also used
culture conditions with withdrawal of growth factors to
study differentiation [28-30]. These showed decreased
expression of cell cycle related genes as well as increased
expression of differentiation markers as a response to the
respective treatments.
Conclusion
In conclusion, we report that using the current study
design, EGF removal in neurosphere culture medium cre-
ates too large transcriptional changes to be able to identify
other parallel transcriptional events relating to
proliferation by PACAP. This requires future development
of modified culture conditions and assay designs to ena-
ble monitoring and proof of these transcriptional
alterations.
Methods
Adult mouse neural stem cell culture
Adult mouse neural stem cell cultures were initiated orig-
inating from tissue isolated from 15 mice using identical
dissection, dissociation and culture protocols. Briefly, the
lateral wall of the lateral ventricle of 6 week-old mice was
enzymatically dissociated in 0.8 mg/ml hyaluronidase
and 0.5 mg/ml trypsin in Dulbecco's modified Eagle
medium (DMEM) containing 4.5 mg/ml glucose and 80
U/ml DNase at 37°C for 20 min. The cells were gently trit-
urated and mixed with three volumes of neurosphere
medium (DMEM/F12, B27 supplement, 12.5 mM HEPES
pH7.4) containing 20 ng/ml EGF, 100 U/ml penicillin
and 100 µg/ml streptomycin. After passing through a 70-
µm strainer, the cells were pelleted at 160 × g for 5 min.
The supernatant was subsequently removed and the cells
resuspended in neurosphere medium supplemented as
above, plated in uncoated culture dishes and incubated at
37°C. Neurospheres were ready to be split 7–8 days after
plating.
To split neurosphere cultures, neurospheres were col-
lected by centrifugation at 160 × g for 5 min. The neuro-
spheres were resuspended in 0.5 ml Trypsin/EDTA in
HBSS (1×), incubated at 37°C for 2 min and triturated
gently to aid dissociation. Following a further three-min
incubation at 37°C and trituration, 3 volumes of ice-cold
neurosphere medium containing EGF were added. The
cells were pelleted at 220 × g for 4 min, resuspended in
fresh neurosphere medium supplemented with 3 nM
EGF.
Dissociated cells were plated and grown in neurosphere
medium supplemented with EGF for a further 3–4 days by
which time secondary neurospheres had developed. Sec-
ondary neurospheres were dissociated and divided into a
4 duplicated fractions. The culture control, proliferation
control and PACAP-treated cultures were grown in neuro-
sphere medium supplemented with 3 nM EGF, 1 nM
transmembrane receptor agonist and 100 nM PACAP,
respectively, for 3 days, and harvested for mRNA isola-
tion. The differentiation control was replated in neuro-
sphere medium supplemented with 1% fetal calf serum
(FCS) onto poly-D-lysine plates to which the cells
adhered. After incubating, overnight FCS concentration
was reduced to 0.5%, and the cells cultured a further 2
days before centrifugation and subsequent mRNA isola-
tion. All experiments were approved by the Karolinska
Institute Ethical Committee.
cDNA synthesis
Messenger RNA was isolated using Dynabeads® mRNA
DIRECT™ Kit from Dynal (Dynal A.S., Norway). First and
RNaseH-dependent second-strand cDNA synthesis
(SuperScript Choice System for cDNA Synthesis) was per-
formed according to the manufacturer's instructions (Inv-
itrogen, Carlsbad, CA, USA) using 45 pmol biotinylated
NotI-oligo(dT) primer (5'-biotin-GAGGTGCCAACCGCG-
GCCGC (T)15-3'). The cDNA was phenol-chloroform
extracted and ethanol precipitated and the pellet was dis-
solved in 40 µl of 1× TE (10 mM Tris-HCl, 1 mM EDTA).
Excess  NotI-oligo(dT) primer was removed by Chro-
maspinn TE-100 column (Clontech, CA, USA)
purification.
Amplification of 3'-end signature tags
The cDNA was fragmented and amplified according to a
protocol previously described [22,23]. Shortly, fragmenta-
tion of the cDNA was performed in 40 µl 1× TE using anBMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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inverted sonication probe, using 16 × 10 s pulses at 90%
effect (Sonifier® B-12, Branson Sonic Power Company, CT,
USA). Biotinylated 3'-end signature tags from the frag-
mented cDNA population were isolated onto 20 µl of par-
amagnetic streptavidin-coated beads (10 mg/ml) (Dynal
A.S.) in 40 µl sample plus 40 µl Binding/Washing buffer
(2 M NaCl, 0.1% Tween-20 in 1× TE, pH 7.7) at 37°C for
one hour with rotation. The immobilised signature tags
were end repaired using 1.5 U T4 DNA polymerase (New
England BioLabs, MA, USA) in a 30-µl reaction volume at
12°C for 20 minutes according to the supplier's recom-
mendations. Blunt-end adapters (Sima18: 5'-GGATC-
CGCGGTG-3'; Sima19: 5'-
TCTCCAGCCTCTCACCGCGGATCC-3') were pre-
annealed and ligated onto the immobilised repaired 3'-
end signature tags using a solution comprising 1.1 nmol
adapter, ligase buffer (66 mM Tris-HCl, pH 7.6, 5 mM
MgCl2, 5 mM DTT, 50 µg/ml BSA), 0.2 mM ATP, 1200 U
T4 DNA ligase (New England BioLabs) in a final volume
of 60 µl. Ligation was performed overnight at room tem-
perature with constant rotation to keep beads in suspen-
sion. The signature tags were released from the magnetic
beads by restriction with NotI (New England BioLabs) for
2 hours in a volume of 60 µl while keeping the beads in
suspension. Five microlitres of the eluate containing the
3'-end signature tags was used as template in a subsequent
PCR. The PCR was performed in 100 µl containing 200
µM of each dNTP, 0.75 µM Sima19, 0.75 µM  NotI-
oligo(dT) primer, 65 mM Tris-HCl, pH 8.8, 4 mM MgCl2,
16 mM (NH4)2SO4, 0.5 µM BSA and 3 U AmpliTaq DNA
polymerase (Perkin Elmer, Boston, USA). Cycling was
performed according to the following procedure, initial
incubation at 72°C for 3 min, followed by addition of Taq
DNA polymerase and subsequent cycling: 72°C for 20
min, 95°C for 1 min, 45°C for 5 min, 72°C for 15 min,
followed by four cycles (95°C for 1 min, 50°C for 1 min,
72°C for 15 min), and 13 cycles (as previously optimised)
(95°C for 1 min, 50°C for 1 min, 72°C for 2 min).
Target labelling and microarray hybridisation
The 3'-end signature tags were purified using QIAquick®
PCR purification kit (Qiagen, Germany). Direct labelling
was performed using Cy3-dCTP or Cy5-dCTP (Perkin
Elmer, Boston, USA) in a linear, asymmetric PCR. The
reaction was performed in a 50-µl labelling mix contain-
ing 100–200 ng purified 3'-end signature tags, 80 µM
dATP, dGTP and dTTP, 20 µM dCTP, 5 µM Sima 19
primer, 2 mM MgCl2, 1 × PCR Buffer II (Applied
Biosystems, Ca, USA), 3 U AmpliTaq Gold® (Applied Bio-
systems) and 60 pM Cy3-dCTP or Cy5-dCTP. The label-
ling mix was cycled as follows: 95°C for 12 min, then 20
cycles (95°C for 30 s, 50°C for 30 s, 72°C for 10 min).
Excess primer and nucleotides were removed using
QIAquick® PCR purification kit. The eluted labelling prod-
ucts were speed vacuumed until dry, then dissolved in 55
µl hybridisation buffer (24% formamide, 5× SSC and
0.1% SDS). Cy-3 and Cy-5 labellings were blended and
mixed with 25 µg mouse Cot-1 DNA (Invitrogen) and 50
µg polyA DNA (Operon Biotechnologies GmbH, Ger-
many). The microarray contained 14121 probes printed
in duplicate and originating mainly from a lateral ventri-
cle wall (Unigene Library ID 16789), a neurosphere (Lib.
16808) and a hematopoietic cell-line cDNA (Lib. 16809)
library. Details regarding the array manufacturing are
available through ArrayExpress (accession number A-
MEXP-175). Briefly, probes were generated through PCR
amplification and subsequent Multiscreen-384 filter
plates (Millipore) purification of the library clones. Puri-
fied products in 50% DMSO were printed onto ultraGAPS
slides (Corning Inc) using the QArray arrayer (Genetix)
and covalently attached to the slide surface using 250 mJ
UV-light (Stratalinker). The arrays were first prehybridised
for 30 min in a 42°C prehybridisation solution (1% BSA,
5× SSC, 0.1% SDS), then washed in water and isopropa-
nol and dried through centrifugation. The sample was
denatured in 95°C for 3 min, applied to the array and
incubated in a hybridisation chamber at 42°C for 18
hours. After hybridisation the arrays were washed in three
successive wash buffers with increasing stringency: (1) 1×
SSC and 0.2% SDS, 42°C, (2) 0.1× SSC and 0.2% SDS,
room temperature, (3) 0.1× SSC, room temperature. All
wash steps were made on a shaking table for 4 min. After
the last step the arrays were immediately centrifuged in a
slide centrifuge and kept in the dark until scanned with
the DNA Microarray scanner G2565BA (Agilent Technol-
ogies, CA, USA).
Image and data analysis
All image and data analysis was conducted in GenePix Pro
5.1 (Axon Instruments Inc, CA, USA) and the R environ-
ment for statistical computing and programming [31]
using packages aroma [32], Bioconductor [33], limma
[25] and kth [34]. The analysis was conducted according
to the following workflow. (1) Spot identity and fore-
ground/background intensities were extracted from the
tiff files using the irregular feature-finding algorithm
implemented in GenePix Pro 5.1. (2) GenePix results files
were imported into R and the median of the foreground
signal was used as expression measurements without sub-
tracting the local background signal. (3) Flagged features
(either automaticly by GenePix or manually by the user),
too small or large features (<51 and >250 µm, respec-
tively), saturated features (both channels > 65100 inten-
sity units) or features for which the signal-to-noise ratio
(as defined by GenePix 5.1) was < 3, were removed from
further analysis. (4) Remaining data was normalised
separately for each block on the slide using the robust
intensity-dependent print-tip lowess normalisation
approach [35]. (5) Differentially expressed genes were
identified using an empirical Bayes moderated t-test [24-BMC Neuroscience 2005, 6:55 http://www.biomedcentral.com/1471-2202/6/55
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26] and ranked in order of evidence for differential expres-
sion. The p-values associated with the t-test were adjusted
for multiple testing by using the Holm's approach [36].
Genes with an adjusted p-value < 0.0001 were considered
differentially expressed. Genes with very small fold-
changes (< 1.5 fold) were excluded by using an additional
M-value cut-off (> +/- 0.6). ESTs on the array were
mapped against build 144 of Mus musculus Unigene.
Over-representation analysis of functional cateogories or
themes was carried out using the EASE software [37].
Themes with an EASE-score < 0.05 were considered over-
represented. The complete set of raw data and trans-
formed data is available through ArrayExpress
(experiment accession number E-MEXP-322).
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Additional File 1
Differentially expressed genes in the NS vs. Diff Cont comparison only. 
Differentially expressed genes (with an M-value > | 0.6 | and a p-value < 
0.0001, calculated by empirical Bayes moderated t-test and a Holm 
adjustment for multiple testing) in the NS vs. Differentiation Control 
only, corresponding to the 79 genes in Fig 5. To facilitate comparisons the 
M- and Holm adjusted p-values for all treatment replicates are provided. 
Genes that have positive M-values are up-regulated in the treated (EGF 
withdrawn) samples, compared to the undifferentiated neurospheres 
(NS). Genes that have negative M-values are up-regulated in the NS 
sample.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-6-55-S1.xls]
Additional File 2
Differentially expressed genes in the NS vs. Proliferation samples only. 
Differentially expressed genes (with an M-value > | 0.6 | and a p-value < 
0.0001, calculated by empirical Bayes moderated t-test and a Holm 
adjustment for multiple testing) in the overlap between the NS vs. PACAP 
and NS vs. Prol Cont comparisons, corresponding to the 151 genes in Fig 
5. To facilitate comparisons the M- and Holm adjusted p-values for all 
treatment replicates are provided. Genes that have positive M-values are 
up-regulated in the treated (EGF withdrawn) samples, compared to the 
undifferentiated neurospheres (NS). Genes that have negative M-values 
are up-regulated in the NS sample.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-6-55-S2.xls]
Additional File 3
Differentially expressed genes in all treatments. Differentially expressed 
genes in the overlap between all treatments (NS vs. PACAP, NS vs. Prol 
Cont and NS vs. Diff Cont). Genes that have positive M-values are up-
regulated in the treated (EGF withdrawn) samples, compared to the 
undifferentiated neurospheres (NS). Genes that have negative M-values 
are up-regulated in the NS sample. Provided are the M-, B- and p-values 
for all treatment replicates, as well as the average M- and B-values and 
their standard deviations. All genes have an M-value > | 0.6 | and a p-
value < 0.0001, calculated by empirical Bayes moderated t-test and a 
Holm adjustment for multiple testing, in all treatments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-6-55-S3.xls]
Additional File 4
GO theme representation among the EGF treatment/withdrawal genes. 
Representation of gene ontology themes among the genes that were differ-
entially expressed in all treatments. Analysis was restricted to themes of 
category biological process. Genes with M-value > | 0.6 | and p < 0.0001, 
calculated by empirical Bayes moderated t-test and a Holm adjustment for 
multiple testing, are included.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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